Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
See more information about Kazia Therapeutics Ltd
Kazia Therapeutics substantial holder increases position
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder The Bank of New York Mellon Corporation has increased its shareholding to 28.54%.
A number of purchases throughout the month of March 2020 has grown the holding from 19.79 million shares to 20.59 million shares.
Trial recruitment recently completed
Kazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain cancer.
The company recently completed recruitment for the phase II clinical trial in newly-diagnosed glioblastoma (aggressive brain cancer).
30 patients were recruited at six sites in the US and the final patient commenced dosing on 27 February 2020.
Kazia has been accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego, CA on 24-29 April 2020.
Other Kazia Therapeutics Ltd news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics raises $1.8 million in well supported share placement
2020-05-06 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04
